Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125876523 | 12587652 | 3 | F | 201404 | 20160902 | 20160725 | 20160914 | EXP | DK-TEVA-678921ISR | TEVA | ANDERSEN N,BOYSEN A,ROSSEN P,LUCKE A,SAFWAT A. BILATERAL AVASCULAR NECROSIS OF THE FEMORAL HEAD FOLLOWING TREATMENT OF EWING^S SARCOMA. ACTA ONCOLOGICA. 2016 JAN 01;55(6):792-795. | 28.00 | YR | M | Y | 0.00000 | 20160914 | MD | DK | DK |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125876523 | 12587652 | 1 | PS | DOXORUBICIN | DOXORUBICIN | 1 | SIX CYCLES;D 1-3 | U | 63097 | 20 | MG/M**2 | ||||||||
| 125876523 | 12587652 | 2 | SS | DOXORUBICIN | DOXORUBICIN | 1 | U | 63097 | |||||||||||
| 125876523 | 12587652 | 3 | SS | IRINOTECAN | IRINOTECAN | 1 | Unknown | 10 MG/M2 ON DAYS 1-5 | U | U | 78122 | ||||||||
| 125876523 | 12587652 | 4 | SS | TEMOZOLOMIDE. | TEMOZOLOMIDE | 1 | Unknown | 100 MG/M2 ON DAYS 1-5 | U | U | 78879 | ||||||||
| 125876523 | 12587652 | 5 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | Unknown | SIX CYCLES (D) D 1-2 | U | U | 0 | 3 | MG/M**2 | ||||||
| 125876523 | 12587652 | 6 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | Unknown | SIX CYCLES (D) 1-3 | U | U | 0 | 3 | MG/M**2 | ||||||
| 125876523 | 12587652 | 7 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | Other | INFUSION: TWO CYCLES; SINGLE AGENT; CONTINUOUS INFUSION BY PUMP | U | U | 0 | INHALANT | |||||||
| 125876523 | 12587652 | 8 | SS | ACTINOMYCIN D | DACTINOMYCIN | 1 | SIX CYCLES; D 1-2 | 0 | .75 | MG/M**2 | |||||||||
| 125876523 | 12587652 | 9 | SS | VINCRISTINE | VINCRISTINE | 1 | Unknown | SIX CYCLES D1 | U | U | 0 | 1.5 | MG/M**2 | ||||||
| 125876523 | 12587652 | 10 | SS | VINCRISTINE | VINCRISTINE | 1 | Unknown | SIX CYCLES D1 | U | U | 0 | 1.5 | MG/M**2 | ||||||
| 125876523 | 12587652 | 11 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Unknown | SIX CYCLES; D 1-3 | U | 0 | 150 | MG/M**2 | |||||||
| 125876523 | 12587652 | 12 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | U | 0 | |||||||||||
| 125876523 | 12587652 | 13 | SS | Dactinomycin | DACTINOMYCIN | 1 | Unknown | 0.75 MG/M2 ON DAY 1-2 | U | U | 0 | ||||||||
| 125876523 | 12587652 | 14 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Unknown | U | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125876523 | 12587652 | 1 | Ewing's sarcoma |
| 125876523 | 12587652 | 2 | Chemotherapy |
| 125876523 | 12587652 | 3 | Chemotherapy |
| 125876523 | 12587652 | 4 | Chemotherapy |
| 125876523 | 12587652 | 5 | Ewing's sarcoma |
| 125876523 | 12587652 | 6 | Chemotherapy |
| 125876523 | 12587652 | 8 | Ewing's sarcoma |
| 125876523 | 12587652 | 9 | Ewing's sarcoma |
| 125876523 | 12587652 | 10 | Chemotherapy |
| 125876523 | 12587652 | 11 | Ewing's sarcoma |
| 125876523 | 12587652 | 12 | Chemotherapy |
| 125876523 | 12587652 | 13 | Chemotherapy |
| 125876523 | 12587652 | 14 | Antiemetic supportive care |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125876523 | 12587652 | OT |
| 125876523 | 12587652 | DS |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125876523 | 12587652 | Osteonecrosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |